Abstract: An antifungal compound of formula (I): or a pharmaceutically acceptable salt thereof, or a pharmaceutically acceptable solvate of either entity, wherein X is CH or N; R1 is phenyl subsituted with 1 to 3 substituents each independently selected from halo and CF3; R2 is (hydroxy)C1-C4 alkyl, CONH2, S(O)m(C1-C4 alkyl), Ar or Het; m is 1 or 2; Ar is phenyl optionally monosubstituted with halo or CF3; and Het is a C-linked 6-membered nitrogen-containing aromatic heterocyclic group containing 1 or 2 nitrogen atoms, or a C- or N-linked 5-membered nitrogen-containing aromatic heterocyclic group containing from 2 to 4 nitrogen atoms, wherein either of said heterocyclic groups is optionally substituted with C1-C4 alkyl or (C1-C4 alkoxy)methyl.

Abstract: Piperidine compounds, processes for preparing them, pharmaceutical compositions comprising them and their use in therapy are disclosed.

Abstract: Piperidine compounds, processes for preparing them, pharmaceutical compositions comprising them and their use in therapy are disclosed.

Abstract: Invented are pharmaceutical compositions containing paroxetine methanesulfonate.

Abstract: A damascene structure, such as a conductive line or via, having a liner with a roughened surface between the substrate and the conductive fill and, preferably, a smooth bottom. The substrate underneath the liner may also have a roughened sidewall and smooth bottom. Such a structure provides enhanced adhesion between one or more layers of the damascene structure. The damascene structure may be manufactured by applying a photoresist over a substrate top surface, exposing the photoresist under conditions that create a standing wave in the resist, and developing the photoresist to provide a pattern having the desired roughened or serrated outline. The pattern is transferred into the substrate, the liner is applied over the substrate bottom and sidewalls, and the liner is filled with conductive material. A roughened liner surface may be achieved by applying a partial layer of liner material over the substrate, removing a portion of the partial layer, and repeating the application and removal steps.

Abstract: Non-crystalline paroxetine hydrochloride is prepared by precipitation of the same as a solid from a solution of paroxetine hydrochloride, or by drying an oil containing paroxetine hydrochloride, or by removing water/solvent from a hydrate/solvate. The oil may also be obtained by precipitation from a solution of paroxetine hydrochloride.

Abstract: Compounds are disclosed which are useful as PDE1 inhibitors.

Abstract: An antifungal compound of formula (I): ##STR1## or a pharmaceutically acceptable salt thereof, or a pharmaceutically acceptable solvate of either entity, wherein X is CH or N; R.sup.1 is phenyl substituted with 1 to 3 substituents each independently selected from halo and CF.sub.3 ; R.sup.2 is (hydroxy)C.sub.1 -C.sub.4 alkyl, CONH.sub.2, S(O).sub.m (C.sub.1 -C.sub.4 alkyl), Ar or Het; m is 1 or 2; Ar is phenyl optionally monosubstituted with halo or CF.sub.3 ; and Het is a C-linked 6-membered nitrogen-containing aromatic heterocyclic group containing 1 or 2 nitrogen atoms, or a C- or N-linked 5-membered nitrogen-containing aromatic heterocyclic group containing from 2 to 4 nitrogen atoms, wherein either of said heterocyclic groups is optionally substituted with C.sub.1 -C.sub.4 alkyl or (C.sub.1 -C.sub.4 alkoxy)methyl.

Abstract: Piperidine compounds, processes for preparing them, pharmaceutical compositions comprising them and their use in therapy are disclosed.

Abstract: The invention relates to compounds of the formula (I) ##STR1## and pharmaceutically acceptable salts thereof, wherein Ar, Z and Het are as defined herein. The compounds of formula (I) possess activity as antifungal agents. The invention also relates to pharmaceutical compositions containing said compounds of formula (I) and to methods of treating fungal infections by administering said compounds of formula (I).

Abstract: An antifungal compound of formula (I): ##STR1## or a pharmaceutically acceptable salt thereof, or a pharmaceutically acceptable solvate of either entity, wherein X is CH or N; R.sup.1 is phenyl substituted with 1 to 3 substituents each independently selected from halo and CF.sub.3 ; R.sup.2 is (hydroxy)C.sub.1 -C.sub.4 alkyl, CONH.sub.2, S(O).sub.m (C.sub.1 -C.sub.4 alkyl), Ar or Het; m is 1 or 2; Ar is phenyl optionally monosubstituted with halo or CF.sub.3 ; and Het is a C-linked 6-membered nitrogen-containing aromatic heterocyclic group containing 1 or 2 nitrogen atoms, or a C- or N-linked 5-membered nitrogen-containing aromatic heterocyclic group containing from 2 to 4 nitrogen atoms, wherein either of said heterocyclic groups is optionally substituted with C.sub.1 -C.sub.4 alkyl or (C.sub.1 -C.sub.4 alkoxy)methyl.

Abstract: Compounds of the formula ##STR1## wherein R.sup.1 is H, C.sub.1 -C.sub.3 alkyl, C.sub.3 -C.sub.5 cycloalkyl or C.sub.1 -C.sub.3 perfluoroalkyl;R.sup.2 is H, C.sub.1 -C.sub.6 alkyl optionally substituted by OH, C.sub.1 -C.sub.3 alkoxy or C.sub.3 -C.sub.6 cycloalkyl, or C.sub.1 -C.sub.3 perfluoroalkyl;R.sup.3 is H, C.sub.1 -C.sub.6 alkyl, C.sub.3 -C.sub.6 alkenyl, C.sub.3 -C.sub.6 alkynyl, C.sub.3 -C.sub.7 cycloalkyl, C.sub.1 -C.sub.6 perfluoroalkyl or (C.sub.3 -C.sub.6 cycloalkyl)C.sub.1 -C.sub.6 alkyl;and Y is chloro, bromo, or fluoro.The above compounds are intermediates useful in the synthesis of certain pyrazolopyrimidinones which inhibit cyclic guanosine 3', 5'-monophosphate phosphodiesterase.

Abstract: The tube bundle is moved out of its shell utilizing a frame structure having a number of movable trollies associated therewith for supporting the tube bundle at spaced points along the length thereof, the trollies having rollers disposed on opposite sides of the central axis of the tube bundle. The tube bundle supported by the trollies is horizontally moved off of the frame structure by rolling the trollies off of the frame structure, preferably onto a protector, and then can be moved to desired maintenance stations. The trollies are latched into place on the protector for movement from station to station. The tube bundle can be transferred from the trollies to a second set of trollies for effecting rotation of the tube bundle about its central axis at the same time that washing fluid is sprayed thereon, and the tube bundle while supported by the trollies may be moved off the protector into an automated cleaning system.